S E Wolowacz

Summary

Affiliation: RTI International
Country: USA

Publications

  1. ncbi Methodologies used in cost-effectiveness models for evaluating treatments in major depressive disorder: a systematic review
    Evelina A Zimovetz
    RTI Health Solutions, The Pavilion, Towers Business Park, Wilmslow Road, Didsbury, Manchester, M20 2LS, UK
    Cost Eff Resour Alloc 10:1. 2012
  2. ncbi Cost effectiveness of pegaptanib for the treatment of age-related macular degeneration in the UK
    Sorrel E Wolowacz
    RTI Health Solutions, Manchester, UK
    Pharmacoeconomics 25:863-79. 2007
  3. ncbi Docetaxel in combination with doxorubicin and cyclophosphamide as adjuvant treatment for early node-positive breast cancer: a cost-effectiveness and cost-utility analysis
    Sorrel E Wolowacz
    RTI Health Solutions, Williams House, University of Manchester Science Park, Manchester M15 6SE, United Kingdom
    J Clin Oncol 26:925-33. 2008
  4. ncbi Cost-effectiveness of venous thromboembolism prophylaxis in total hip and knee replacement surgery: the evolving application of health economic modelling over 20 years
    S E Wolowacz
    RTI Health Solutions, Williams House, Manchester University Science Park, Lloyd Street North, Manchester, UK
    Curr Med Res Opin 24:2993-3006. 2008
  5. ncbi Efficacy and safety of dabigatran etexilate for the prevention of venous thromboembolism following total hip or knee arthroplasty. A meta-analysis
    Sorrel E Wolowacz
    RTI Health Solutions, Williams House, Lloyd St, North Manchester, Manchester M15 6SE, United Kingdom
    Thromb Haemost 101:77-85. 2009
  6. ncbi Economic evaluation of dabigatran etexilate for the prevention of venous thromboembolism after total knee and hip replacement surgery
    Sorrel E Wolowacz
    RTI Health Solutions, Manchester, UK
    Clin Ther 31:194-212. 2009
  7. ncbi Economic evaluation of dabigatran etexilate for the prevention of venous thromboembolism in patients aged over 75 years or with moderate renal impairment undergoing total knee or hip replacement
    S E Wolowacz
    Williams House, Manchester University Science Park, Lloyd Street North, Manchester M15 6SE, UK
    Thromb Haemost 103:360-71. 2010
  8. ncbi Pharmacoeconomics of dabigatran etexilate for prevention of thromboembolism after joint replacement surgery
    Sorrel E Wolowacz
    RTI Health Solutions, Williams House, Manchester University Science Park, Lloyd Street North, Manchester, M15 6SE, UK
    Expert Rev Pharmacoecon Outcomes Res 11:9-25. 2011
  9. ncbi The cost of illness of atrial fibrillation: a systematic review of the recent literature
    S E Wolowacz
    RTI Health Solutions, The Pavilion, Towers Business Park, Didsbury, Manchester M20 2LS, UK Email
    Europace 13:1375-85. 2011

Detail Information

Publications9

  1. ncbi Methodologies used in cost-effectiveness models for evaluating treatments in major depressive disorder: a systematic review
    Evelina A Zimovetz
    RTI Health Solutions, The Pavilion, Towers Business Park, Wilmslow Road, Didsbury, Manchester, M20 2LS, UK
    Cost Eff Resour Alloc 10:1. 2012
    ..abstract:..
  2. ncbi Cost effectiveness of pegaptanib for the treatment of age-related macular degeneration in the UK
    Sorrel E Wolowacz
    RTI Health Solutions, Manchester, UK
    Pharmacoeconomics 25:863-79. 2007
    ..Guidance is needed regarding the cost effectiveness of treatment, any variation between sub-populations of differing clinical characteristics and the optimum duration of treatment...
  3. ncbi Docetaxel in combination with doxorubicin and cyclophosphamide as adjuvant treatment for early node-positive breast cancer: a cost-effectiveness and cost-utility analysis
    Sorrel E Wolowacz
    RTI Health Solutions, Williams House, University of Manchester Science Park, Manchester M15 6SE, United Kingdom
    J Clin Oncol 26:925-33. 2008
    ....
  4. ncbi Cost-effectiveness of venous thromboembolism prophylaxis in total hip and knee replacement surgery: the evolving application of health economic modelling over 20 years
    S E Wolowacz
    RTI Health Solutions, Williams House, Manchester University Science Park, Lloyd Street North, Manchester, UK
    Curr Med Res Opin 24:2993-3006. 2008
    ..Our objectives are to document evolving methodology by describing VTE models, assess their critical strengths and weaknesses, and inform future advances for models in this therapeutic area...
  5. ncbi Efficacy and safety of dabigatran etexilate for the prevention of venous thromboembolism following total hip or knee arthroplasty. A meta-analysis
    Sorrel E Wolowacz
    RTI Health Solutions, Williams House, Lloyd St, North Manchester, Manchester M15 6SE, United Kingdom
    Thromb Haemost 101:77-85. 2009
    ..Meta-analysis of all three trials found no significant differences between treatments in any of the end-points analysed. Heterogeneity between the trials cannot be ruled out...
  6. ncbi Economic evaluation of dabigatran etexilate for the prevention of venous thromboembolism after total knee and hip replacement surgery
    Sorrel E Wolowacz
    RTI Health Solutions, Manchester, UK
    Clin Ther 31:194-212. 2009
    ....
  7. ncbi Economic evaluation of dabigatran etexilate for the prevention of venous thromboembolism in patients aged over 75 years or with moderate renal impairment undergoing total knee or hip replacement
    S E Wolowacz
    Williams House, Manchester University Science Park, Lloyd Street North, Manchester M15 6SE, UK
    Thromb Haemost 103:360-71. 2010
    ..Dabigatran etexilate 150 mg od is cost saving compared with enoxaparin 40 mg od in patients aged over 75years and in patients with moderate renal impairment, with comparable efficacy and safety...
  8. ncbi Pharmacoeconomics of dabigatran etexilate for prevention of thromboembolism after joint replacement surgery
    Sorrel E Wolowacz
    RTI Health Solutions, Williams House, Manchester University Science Park, Lloyd Street North, Manchester, M15 6SE, UK
    Expert Rev Pharmacoecon Outcomes Res 11:9-25. 2011
    ..This article presents an overview of the clinical evidence for DE and a systematic review of the economic evaluations of the drug...
  9. ncbi The cost of illness of atrial fibrillation: a systematic review of the recent literature
    S E Wolowacz
    RTI Health Solutions, The Pavilion, Towers Business Park, Didsbury, Manchester M20 2LS, UK Email
    Europace 13:1375-85. 2011
    ..Costs and hospitalizations attributable to AF have increased markedly over recent decades and are expected to increase in future due to ageing populations...